ANNOUNCEMENT

Save $300 on MedCity CONVERGE Healthcare Innovation Summit July 9-10 in Philadelphia. Earlybird rate ends May 20.

Topic: Navidea Biopharmaceuticals

Navidea cancer imaging agent may see wider use

Navidea cancer imaging agent may see wider use

April 4, 2013 8:02 am by | 0 Comments

Navidea Biopharmaceuticals Inc said its cancer diagnostic agent was effective in identifying the first lymph node reached by the disease in patients with head and neck cancer, paving the way ... Read more
This time, FDA says yes to Navidea Biopharmaceuticals’ Lymphoseek

This time, FDA says yes to Navidea Biopharmaceuticals’ Lymphoseek

March 13, 2013 5:41 pm by | 0 Comments

After more than a decade of development and a couple regulatory delays, Navidea Biopharmaceuticals (NYSE:NAVB) finally got the FDA approval it needs to begin marketing its radiopharmaceutical Lymphoseek.In a conference ... Read more
$NAVB sees mixed reactions from twitterverse after FDA rejects Lymphoseek

$NAVB sees mixed reactions from twitterverse after FDA rejects Lymphoseek

September 11, 2012 2:52 pm by | 0 Comments

Shares of Navidea Biopharmaceuticals (NYSEAMEX:NAVB) went tumbling in after-hours Monday when the company announced that the U.S. Food and Drug Administration did not approve its cancer diagnostic Lymphoseek.Navidea received a ... Read more
Navidea Biopharma: FDA pushes back PDUFA date of cancer drug

Navidea Biopharma: FDA pushes back PDUFA date of cancer drug

April 3, 2012 10:43 am by | 0 Comments

Radiopharmaceuticals company Navidea Biopharmaceuticals (NYSE Amex:NAVB) announced that the PDUFA date for its cancer diagnostics drug Lymphoseek has been pushed back three months to Sept. 10.The reason Dublin, Ohio-based Navidea ... Read more
Navidea Biopharma touts early results of head and neck cancer clinical trial

Navidea Biopharma touts early results of head and neck cancer clinical trial

March 28, 2012 11:30 am by | 0 Comments

Radiopharmaceuticals developer Navidea Biopharmaceuticals (NYSE Amex:NAVB) said early results from a phase 3 clinical study suggest that a targeting agent from the company could be effective in detecting head and ... Read more
Navidea Biopharma: Cardinal Health to have final say in pricing of cancer drug

Navidea Biopharma: Cardinal Health to have final say in pricing of cancer drug

March 5, 2012 1:08 pm by | 0 Comments

Cardinal Health (NYSE:CAH) will set the price for Navidea Biopharmaceuticals‘ (NYSE Amex:NAVB) cancer drug that could be approved as soon as this summer.While Navidea, developed the drug, called Lymphoseek, Cardinal ... Read more
Navidea Biopharmaceuticals opens Boston commercialization office

Navidea Biopharmaceuticals opens Boston commercialization office

February 8, 2012 9:09 am by | 0 Comments

Radiopharmaceuticals company Navidea Biopharmaceuticals (NYSE Amex:NAVB) has opened a Boston-area commercialization office.Employees at Navidea’s new Andover, Massachusetts office will focus much of their attention on the expected launch later this ... Read more
Public ethics group calls for SEC inquiry into Navidea short seller

Public ethics group calls for SEC inquiry into Navidea short seller

January 26, 2012 1:27 pm by | 1 Comments

A public ethics group is calling on the U.S. Securities and Exchange Commission to investigate a hedge fund manager who made headlines last year for being an outspoken short seller ... Read more
Navidea signs option to license Parkinson’s imaging agent from Alseres

Navidea signs option to license Parkinson’s imaging agent from Alseres

January 25, 2012 5:11 pm by | 0 Comments

Radiopharmaceuticals developer Navidea Biopharmaceuticals (NYSE Amex:NAVB) has signed a deal that gives it the option to license a Parkinson’s disease imaging agent from Alseres Pharmaceuticals.Under the terms of the deal, ... Read more
Navidea formally changes name from Neoprobe, gets $10M in debt financing

Navidea formally changes name from Neoprobe, gets $10M in debt financing

January 5, 2012 9:11 am by | 0 Comments

Radiopharmaceuticals developer Navidea Biopharmaceuticals (NYSE Amex:NAVB) has secured up to $10 million in debt financing that strengthens the company’s balance sheet and could help with future acquisitions or licensing deals.The ... Read more
Neoprobe: Alzheimer’s diagnosis agent has market potential exceeding $1B

Neoprobe: Alzheimer’s diagnosis agent has market potential exceeding $1B

December 13, 2011 10:25 am by | 0 Comments

Neoprobe‘s (NYSE Amex:NEOP) newly licensed drug candidate that could aid in the diagnosis of Alzheimer’s disease has a potential worldwide market of more than $1 billion, a company official said.Further, ... Read more
Neoprobe licenses Alzheimer’s diagnosis imaging agent from AZN

Neoprobe licenses Alzheimer’s diagnosis imaging agent from AZN

December 12, 2011 7:40 pm by | 0 Comments

Neoprobe (NYSE Amex:NEOP) has licensed from AstraZeneca (NYSE:AZN) the worldwide rights to an imaging drug candidate that could aid in the diagnosis of Alzheimer’s disease.Neoprobe said it plans to begin ... Read more
Neoprobe unveils new name: Navidea Biopharmaceuticals

Neoprobe unveils new name: Navidea Biopharmaceuticals

December 8, 2011 11:59 am by | 0 Comments

Cancer diagnostics company Neoprobe (NYSE Amex:NEOP) has a new name: Navidea Biopharmaceuticals.The Dublin, Ohio company chose the new moniker because it represents Neoprobe’s commitment to “NAVigating IDEAs” that translate innovation ... Read more